guest ::
| Home > Publications Database > Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction. > print |
| Home > Publications Database > Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction. > print |
| 001 | 164071 | ||
| 005 | 20240826165946.0 | ||
| 024 | 7 | _ | |a pmc:PMC9128811 |2 pmc |
| 024 | 7 | _ | |a 10.1093/brain/awab405 |2 doi |
| 024 | 7 | _ | |a pmid:35352105 |2 pmid |
| 024 | 7 | _ | |a 0006-8950 |2 ISSN |
| 024 | 7 | _ | |a 1460-2156 |2 ISSN |
| 024 | 7 | _ | |a altmetric:125590302 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00734 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Düzel, Emrah |0 P:(DE-2719)2000005 |b 0 |e First author |u dzne |
| 245 | _ | _ | |a Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction. |
| 260 | _ | _ | |a Oxford |c 2022 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1709568236_22645 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a (CC BY-NC) |
| 520 | _ | _ | |a We investigated whether the impact of tau-pathology on memory performance and on hippocampal/medial temporal memory function in non-demented individuals depends on the presence of amyloid pathology, irrespective of diagnostic clinical stage. We conducted a cross-sectional analysis of the observational, multicentric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE). Two hundred and thirty-five participants completed task functional MRI and provided CSF (92 cognitively unimpaired, 100 experiencing subjective cognitive decline and 43 with mild cognitive impairment). Presence (A+) and absence (A-) of amyloid pathology was defined by CSF amyloid-β42 (Aβ42) levels. Free recall performance in the Free and Cued Selective Reminding Test, scene recognition memory accuracy and hippocampal/medial temporal functional MRI novelty responses to scene images were related to CSF total-tau and phospho-tau levels separately for A+ and A- individuals. We found that total-tau and phospho-tau levels were negatively associated with memory performance in both tasks and with novelty responses in the hippocampus and amygdala, in interaction with Aβ42 levels. Subgroup analyses showed that these relationships were only present in A+ and remained stable when very high levels of tau (>700 pg/ml) and phospho-tau (>100 pg/ml) were excluded. These relationships were significant with diagnosis, age, education, sex, assessment site and Aβ42 levels as covariates. They also remained significant after propensity score based matching of phospho-tau levels across A+ and A- groups. After classifying this matched sample for phospho-tau pathology (T-/T+), individuals with A+/T+ were significantly more memory-impaired than A-/T+ despite the fact that both groups had the same amount of phospho-tau pathology. ApoE status (presence of the E4 allele), a known genetic risk factor for Alzheimer's disease, did not mediate the relationship between tau pathology and hippocampal function and memory performance. Thus, our data show that the presence of amyloid pathology is associated with a linear relationship between tau pathology, hippocampal dysfunction and memory impairment, although the actual severity of amyloid pathology is uncorrelated. Our data therefore indicate that the presence of amyloid pathology provides a permissive state for tau-related hippocampal dysfunction and hippocampus-dependent recognition and recall impairment. This raises the possibility that in the predementia stage of Alzheimer's disease, removing the negative impact of amyloid pathology could improve memory and hippocampal function even if the amount of tau-pathology in CSF is not changed, whereas reducing increased CSF tau-pathology in amyloid-negative individuals may not proportionally improve memory function. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 354 - Disease Prevention and Healthy Aging (POF4-354) |0 G:(DE-HGF)POF4-354 |c POF4-354 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Alzheimer’s disease biomarker |2 Other |
| 650 | _ | 7 | |a hippocampus |2 Other |
| 650 | _ | 7 | |a memory |2 Other |
| 650 | _ | 7 | |a mild cognitive impairment |2 Other |
| 650 | _ | 7 | |a subjective cognitive decline |2 Other |
| 650 | _ | 2 | |a Alzheimer Disease: pathology |2 MeSH |
| 650 | _ | 2 | |a Amyloid beta-Peptides: metabolism |2 MeSH |
| 650 | _ | 2 | |a Amyloidogenic Proteins |2 MeSH |
| 650 | _ | 2 | |a Amyloidosis |2 MeSH |
| 650 | _ | 2 | |a Apolipoproteins E: genetics |2 MeSH |
| 650 | _ | 2 | |a Biomarkers |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Cognitive Dysfunction: genetics |2 MeSH |
| 650 | _ | 2 | |a Cross-Sectional Studies |2 MeSH |
| 650 | _ | 2 | |a Hippocampus: metabolism |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a tau Proteins: metabolism |2 MeSH |
| 693 | _ | _ | |0 EXP:(DE-2719)DELCODE-20140101 |5 EXP:(DE-2719)DELCODE-20140101 |e Longitudinal Cognitive Impairment and Dementia Study |x 0 |
| 700 | 1 | _ | |a Ziegler, Gabriel |0 P:(DE-2719)2814076 |b 1 |u dzne |
| 700 | 1 | _ | |a Berron, David |0 P:(DE-2719)2812972 |b 2 |u dzne |
| 700 | 1 | _ | |a Maaß, Anne |0 P:(DE-2719)2811815 |b 3 |u dzne |
| 700 | 1 | _ | |a Schütze, Hartmut |0 P:(DE-2719)9001467 |b 4 |u dzne |
| 700 | 1 | _ | |a Cardenas-Blanco, Arturo |0 P:(DE-2719)2810750 |b 5 |u dzne |
| 700 | 1 | _ | |a Glanz, Wenzel |0 P:(DE-2719)2811614 |b 6 |u dzne |
| 700 | 1 | _ | |a Metzger, Coraline |0 P:(DE-2719)9000443 |b 7 |u dzne |
| 700 | 1 | _ | |a Dobisch, Laura |0 P:(DE-2719)2811611 |b 8 |u dzne |
| 700 | 1 | _ | |a Reuter, Martin |0 P:(DE-2719)2812134 |b 9 |u dzne |
| 700 | 1 | _ | |a Spottke, Annika |0 P:(DE-2719)2811324 |b 10 |u dzne |
| 700 | 1 | _ | |a Brosseron, Frederic |0 P:(DE-2719)2810593 |b 11 |u dzne |
| 700 | 1 | _ | |a Fliessbach, Klaus |0 P:(DE-2719)2811326 |b 12 |u dzne |
| 700 | 1 | _ | |a Heneka, Michael T |0 P:(DE-2719)2000008 |b 13 |u dzne |
| 700 | 1 | _ | |a Laske, Christoph |0 P:(DE-2719)2000055 |b 14 |u dzne |
| 700 | 1 | _ | |a Peters, Oliver |0 P:(DE-2719)2811024 |b 15 |u dzne |
| 700 | 1 | _ | |a Priller, Josef |0 P:(DE-2719)2811122 |b 16 |u dzne |
| 700 | 1 | _ | |a Spruth, Eike Jakob |0 P:(DE-2719)2812446 |b 17 |u dzne |
| 700 | 1 | _ | |a Ramirez, Alfredo |0 P:(DE-2719)2812825 |b 18 |u dzne |
| 700 | 1 | _ | |a Speck, Oliver |0 P:(DE-2719)2810706 |b 19 |u dzne |
| 700 | 1 | _ | |a Schneider, Anja |0 P:(DE-2719)2812035 |b 20 |u dzne |
| 700 | 1 | _ | |a Teipel, Stefan |0 P:(DE-2719)2000026 |b 21 |u dzne |
| 700 | 1 | _ | |a Kilimann, Ingo |0 P:(DE-2719)2810394 |b 22 |u dzne |
| 700 | 1 | _ | |a Wiltfang, Jens |0 P:(DE-2719)2811317 |b 23 |u dzne |
| 700 | 1 | _ | |a Schott, Björn |0 P:(DE-2719)2814326 |b 24 |u dzne |
| 700 | 1 | _ | |a Preis, Lukas |0 P:(DE-2719)9000703 |b 25 |u dzne |
| 700 | 1 | _ | |a Gref, Daria |0 P:(DE-2719)9001704 |b 26 |u dzne |
| 700 | 1 | _ | |a Maier, Franziska |b 27 |
| 700 | 1 | _ | |a Munk, Matthias H |0 P:(DE-2719)9001516 |b 28 |u dzne |
| 700 | 1 | _ | |a Roy, Nina |0 P:(DE-2719)2812341 |b 29 |u dzne |
| 700 | 1 | _ | |a Ballarini, Tomasso |0 P:(DE-HGF)0 |b 30 |
| 700 | 1 | _ | |a Yakupov, Renat |0 P:(DE-2719)2812398 |b 31 |u dzne |
| 700 | 1 | _ | |a Haynes, John Dylan |b 32 |
| 700 | 1 | _ | |a Dechent, Peter |b 33 |
| 700 | 1 | _ | |a Scheffler, Klaus |b 34 |
| 700 | 1 | _ | |a Wagner, Michael |0 P:(DE-2719)2000057 |b 35 |u dzne |
| 700 | 1 | _ | |a Jessen, Frank |0 P:(DE-2719)2000032 |b 36 |e Last author |u dzne |
| 773 | _ | _ | |a 10.1093/brain/awab405 |g p. awab405 |0 PERI:(DE-600)1474117-9 |n 4 |p 1473-1485 |t Brain |v 145 |y 2022 |x 0006-8950 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/164071/files/DZNE-2022-00734.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/164071/files/DZNE-2022-00734.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:164071 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 0 |6 P:(DE-2719)2000005 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 1 |6 P:(DE-2719)2814076 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2812972 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 3 |6 P:(DE-2719)2811815 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 4 |6 P:(DE-2719)9001467 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2810750 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 6 |6 P:(DE-2719)2811614 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)9000443 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 8 |6 P:(DE-2719)2811611 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 9 |6 P:(DE-2719)2812134 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)2811324 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 11 |6 P:(DE-2719)2810593 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 12 |6 P:(DE-2719)2811326 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2000008 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 14 |6 P:(DE-2719)2000055 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2811024 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 16 |6 P:(DE-2719)2811122 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 17 |6 P:(DE-2719)2812446 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 18 |6 P:(DE-2719)2812825 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 19 |6 P:(DE-2719)2810706 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 20 |6 P:(DE-2719)2812035 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 21 |6 P:(DE-2719)2000026 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 22 |6 P:(DE-2719)2810394 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 23 |6 P:(DE-2719)2811317 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 24 |6 P:(DE-2719)2814326 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)9000703 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 26 |6 P:(DE-2719)9001704 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 28 |6 P:(DE-2719)9001516 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 29 |6 P:(DE-2719)2812341 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 31 |6 P:(DE-2719)2812398 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 35 |6 P:(DE-2719)2000057 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 36 |6 P:(DE-2719)2000032 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 1 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-09 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b BRAIN : 2021 |d 2022-11-09 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRAIN : 2021 |d 2022-11-09 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-09 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-09 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-09 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-09 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-09 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-09 |
| 920 | 1 | _ | |0 I:(DE-2719)5000006 |k AG Düzel |l Clinical Neurophysiology and Memory |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1011102 |k AG Jessen |l Clinical Alzheimer’s Disease Research |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)5000070 |k AG Berron |l Clinical Cognitive Neuroscience |x 2 |
| 920 | 1 | _ | |0 I:(DE-2719)1340009 |k AG Speck |l Linking imaging projects iNET |x 3 |
| 920 | 1 | _ | |0 I:(DE-2719)1340013 |k KAP |l Cooperation Unit for Applied Prevention Research (KAP) |x 4 |
| 920 | 1 | _ | |0 I:(DE-2719)6000015 |k Magdeburg common |l Magdeburg common |x 5 |
| 920 | 1 | _ | |0 I:(DE-2719)1040310 |k AG Reuter |l Artificial Intelligence in Medicine |x 6 |
| 920 | 1 | _ | |0 I:(DE-2719)1011001 |k AG Klockgether |l Patient Studies |x 7 |
| 920 | 1 | _ | |0 I:(DE-2719)1011301 |k Biomarker |l Interventional Trials and Biomarkers in Neurodegenerative Diseases |x 8 |
| 920 | 1 | _ | |0 I:(DE-2719)1011101 |k Patient Studies Bonn |l Patient Studies Bonn |x 9 |
| 920 | 1 | _ | |0 I:(DE-2719)1240005 |k Core ICRU |l Core ICRU |x 10 |
| 920 | 1 | _ | |0 I:(DE-2719)1811005 |k AG Endres |l Interdisciplinary Dementia Research |x 11 |
| 920 | 1 | _ | |0 I:(DE-2719)1011305 |k AG Schneider |l Translational Dementia Research (Bonn) |x 12 |
| 920 | 1 | _ | |0 I:(DE-2719)1510100 |k AG Teipel |l Clinical Dementia Research (Rostock /Greifswald) |x 13 |
| 920 | 1 | _ | |0 I:(DE-2719)1410006 |k AG Wiltfang |l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases |x 14 |
| 920 | 1 | _ | |0 I:(DE-2719)1410002 |k AG Fischer |l Epigenetics and Systems Medicine in Neurodegenerative Diseases |x 15 |
| 920 | 1 | _ | |0 I:(DE-2719)1210000 |k AG Gasser |l Parkinson Genetics |x 16 |
| 920 | 1 | _ | |0 I:(DE-2719)1011401 |k Clinical Research Platform (CRP) |l Clinical Research Platform (CRP) |x 17 |
| 920 | 1 | _ | |0 I:(DE-2719)1011201 |k AG Wagner |l Neuropsychology |x 18 |
| 920 | 1 | _ | |0 I:(DE-2719)5000034 |k Delcode |l Delcode |x 19 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)5000006 |
| 980 | _ | _ | |a I:(DE-2719)1011102 |
| 980 | _ | _ | |a I:(DE-2719)5000070 |
| 980 | _ | _ | |a I:(DE-2719)1340009 |
| 980 | _ | _ | |a I:(DE-2719)1340013 |
| 980 | _ | _ | |a I:(DE-2719)6000015 |
| 980 | _ | _ | |a I:(DE-2719)1040310 |
| 980 | _ | _ | |a I:(DE-2719)1011001 |
| 980 | _ | _ | |a I:(DE-2719)1011301 |
| 980 | _ | _ | |a I:(DE-2719)1011101 |
| 980 | _ | _ | |a I:(DE-2719)1240005 |
| 980 | _ | _ | |a I:(DE-2719)1811005 |
| 980 | _ | _ | |a I:(DE-2719)1011305 |
| 980 | _ | _ | |a I:(DE-2719)1510100 |
| 980 | _ | _ | |a I:(DE-2719)1410006 |
| 980 | _ | _ | |a I:(DE-2719)1410002 |
| 980 | _ | _ | |a I:(DE-2719)1210000 |
| 980 | _ | _ | |a I:(DE-2719)1011401 |
| 980 | _ | _ | |a I:(DE-2719)1011201 |
| 980 | _ | _ | |a I:(DE-2719)5000034 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|